


## Tazarotenic acid

<b>Cat. No.:</b>	HY-101108		
<b>CAS No.:</b>	118292-41-4		
<b>Molecular Formula:</b>	C <sub>19</sub> H <sub>17</sub> NO <sub>2</sub> S		
<b>Molecular Weight:</b>	323.41		
<b>Target:</b>	Drug Metabolite		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (309.21 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.0921 mL	15.4603 mL	30.9205 mL
	5 mM	0.6184 mL	3.0921 mL	6.1841 mL
	10 mM	0.3092 mL	1.5460 mL	3.0921 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Tazarotenic acid is the metabolite of Tazarotene. Tazarotenic acid binding to retinoic acid receptors (RARs) is the probable molecular target of retinoid action. Tazarotenic acid has the potential for the research of warty dyskeratoma<sup>[1][2][3]</sup>.

#### In Vivo

Assessment of Pharmacokinetics (PK) profile of Tazarotenic acid (Compound AGN 190299) after an intravenous of AGN 190168 in rats<sup>[1]</sup>

	Male	Female	Male
Dose (mg kg <sup>-1</sup> )	4.4	4.4	0.49
AUC (µg h mL <sup>-1</sup> )	9.31 (2.14)	9.78 (1.36)	0.594 (0.95)

CL (mL min <sup>-1</sup> kg <sup>-1</sup> )	7.96 (1.59)	7.62 (0.85)	14.0 (2.2)
k (h <sup>-1</sup> )	0.562 (0.339)	0.820 (0.146)	0.741 (0.115)
T <sub>1/2</sub> (h)	1.64 (0.92)	0.86 (0.14)	0.95 (0.16)
V <sub>0</sub> (L kg <sup>-1</sup> )	0.43 (0.05)	0.49 (0.06)	1.31 (1.15)
V <sub>β</sub> (L kg <sup>-1</sup> )	-	-	1.14 (0.09)
V <sub>max</sub> (μg min <sup>-1</sup> )	9.08 (2.89)	6.09 (1.22)	-
K <sub>m</sub> (μg mL <sup>-1</sup> )	7.09 (1.35)	5.12 (1.19)	-

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

- [1]. Chandraratna RA. Tazarotene—first of a new generation of receptor-selective retinoids. *Br J Dermatol.* 1996;135 Suppl 49:18-25.
- [2]. Hsyu PH, et al. Pharmacokinetics of a novel retinoid AGN 190168 and its metabolite AGN 190299 after intravenous administration of AGN 190168 to rats. *Biopharm Drug Dispos.* 1994;15(5):347-357.
- [3]. Abramovits W, et al. Treatment of warty dyskeratoma with tazarotenic acid. *J Am Acad Dermatol.* 2002;46(2 Suppl Case Reports):S4.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA